

## Boston Biomedical Consultants Incorporated

[View the current Boston Biomedical Consultants Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/2103-Boston+Biomedical+Consultants+Incorporated.html)

(<http://www.bioportfolio.com/bioporporate/2103-Boston+Biomedical+Consultants+Incorporated.html>)

### Contact Details:

100 Fifth Avenue

Waltham

MA

02154

United States of America

Tel: 617 890 5060

Fax: 617 890 6746

Email:

### Recent Publications by Boston Biomedical Consultants Incorporated:



- [Patch-pump technology to manage type 2 diabetes mellitus: hurdles to market acceptance.](#)  
*The recent development of novel "patch"-type insulin infusion pump (IIP)...*4th November, 2009  
Boston Biomedical Consultants , Waltham, Massachusetts.- J Diabetes Sci Technol. 2008  
Nov;2(6):1147-50.
- [Convergence of Continuous Glucose Monitoring and In-Hospital Tight Glycemic Control: Closing the Gap between Caregivers and Industry.](#)  
*The convergence of continuous glucose monitoring (CGM) and tight glycemic...*1st November, 2007  
Boston Biomedical Consultants , Waltham, Massachusetts.- J Diabetes Sci Technol. 2007  
Nov;1(6):903-6.

### Press Releases on Boston Biomedical Consultants Incorporated:

<a href="#">FDA Accepts Once Daily 23mg Aricept(R) Extended Release NDA for Review</a>	24th November, 2009	Eisai Inc.	WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug
<a href="#">Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference</a>	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
<a href="#">Prodesse's ProParafly(TM) Assay Cleared for US Marketing by FDA</a>	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
<a href="#">NIP Acquires San Diego Executive Benefits Firm</a>	24th November, 2009	NIP, Inc.	AUSTIN, Texas, Nov. 24 /PRNewswire/ -- NIP, Inc. today announced the acquisition of Retirement Capital Group ["RCG"], one of the nation's leading executive compensation and benefit plan
<a href="#">Hays Companies, National Employer Advocate: 'We Can't Avoid the Elephants in the Room When Reforming Healthcare'</a>	24th November, 2009	Hays Companies	BOSTON, Nov. 24 /PRNewswire/ -- If you ask Eric Kasen, Vice President and principal of the New England office of Hays Companies, America's national healthcare conversation has been held as if

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

